AAT-AD/PD 2018*: An Update on Scientific Advances and Clinical Strategies in Alzheimer’s Disease

The AAT-AD/PDTM Focus Meeting 2018 was held in Turin, Italy, March 15-18, 2018. During the new joint meeting between the International Geneva/Springfield Symposium on Advances in Alzheimer Therapy (AAT) and AD/PD,TM the latest breakthroughs in treatment, translational R&D, early diagnosis, drug development, and clinical trials in Alzheimer's, Parkinson's, and other related neurological disorders were at the forefront of the meeting. In this activity, 2 experts summarize the key learnings from this year’s conference focusing on AD.

*This webcast is not endorsed by the conference organizer. Elsevier Office of Continuing Medical Education is an independent medical education company that provides clinical updates, analysis, and expert perspectives through conference coverage educational programs.


This activity has been designed to meet the educational needs of health care professionals involved in the diagnosis, treatment, or management of patients with Alzheimer’s disease or other dementias across the disease continuum.


Upon completion of this activity, participants will be better able to do the following:

  • Identify therapies in development for the treatment of AD
  • Analyze advances in the development of biomarkers to diagnose AD and to evaluate and monitor interventions


Jeffrey L. Cummings, MD, ScD
Cleveland Clinic Lerner College of Medicine
Cleveland, Ohio
Camille and Larry Ruvo Chair for Brain Health
Cleveland Clinic Lou Ruvo Center for Brain Health
Center for Neurodegeneration and Translational Neuroscience
Las Vegas, Nevada

Lawrence S. Honig, MD, PhD, FAAN
Professor of Neurology
Columbia University Medical Center
Columbia University College of Physicians and Surgeons
Associate Attending Neurologist
New York Presbyterian Hospital
New York, New York

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or PresenterRelationship Identified With:
Jeffrey L. Cummings, MD, ScD

Consultant/Advisor: ACADIA Pharmaceuticals Inc, Accera, Inc, Actinogen Medical, Adamas Pharmaceuticals, Inc, Alkahest, Inc, Allergan plc, Alzheon, Inc, Avanir Pharmaceuticals, Inc, Axovant Sciences Ltd, Axsome Therapeutics, Inc, Bioasis Technologies, Inc., Biogen, Boehringer Ingelheim GmbH, Bracket, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Genentech, Inc, Grifols, Kyowa Kirin International plc., Lundbeck LLC, Medavante Inc, Merck & Co., Inc., Neurocog, NUTRICIA, Otsuka America Pharmaceutical, Inc, QR Pharma, Inc, Resverlogix Corp., Servier, Suven Life Sciences Limited, Takeda Pharmaceutical Company Limited, Toyoma, United Neuroscience, Inc

Stock Ownership: Adamas Pharmaceuticals, Inc, Alzheon, Inc, Bioasis Technologies, Inc., EIP Pharma, LLC, Prana Biotechnology Limited, Sonexa Therapeutics

Royalties/Patents: Copyright ownership of the Neuropsychiatric Inventory (NPI)

Research Grant: Avid Radiopharmaceuticals, Teva Pharmaceutical Industries Ltd.

Lawrence S. Honig, MD, PhD, FAAN

Consultant/Advisor: Bristol-Myers Squibb Company, Eisai Co., Ltd, Eli Lilly and Company

Grant/Research Support: AbbVie Inc., AstraZeneca, Biogen, Bristol-Myers Squibb Company, Eisai Co., Ltd, Eli Lilly and Company, F. Hoffman-La Roche Ltd, FORUM Pharmaceuticals Inc., Genentech, Inc., Lundbeck LLC, Merck & Co., Inc., TauRx

Non-faculty: Lyerka Miller, PhD; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD, hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by independent educational grants from Avanir Pharmaceuticals and Biogen.

Provider Information

Jointly provided by the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC.

CME Credit (Physicians)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.

Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Miller Medical Communications, LLC, Avanir Pharmaceuticals and Biogen do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician
Course opens: 
Course expires: 

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician
Please login or register to take this course.